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Summary.-The concentration of desmethylmisonidazole (DESMISO) was deter-
mined in 60 biopsy samples taken from 13 human tumours and in cerebrospinal fluid
(CSF) from 8 patients after oral administration. In comparison with misonidazole
(MISO), peak concentrations in plasma were reached at earlier times and half-lives
were shorter, so that the area under the curve of plasma concentration with time
(AUC) was reduced by45%0; the AUC of CSF concentration with time was reduced by
6700. Between 1 and 2 h after administration ofDESMISO, concentrations in tumours
were generally 85-90% of those of MISO estimated ~4 h after it was given. The two
drugs when tested in equimolar concentrations have been found in laboratory experi-
ment to be equally potent as hypoxic cell radiosensitizers. Recognizing the lower
mol. wt of DESMISO and the trend to higher concentrations in the more necrotic
areas of the tumours studied, equal doses by weight of the two drugs given orally
may give equal radiosensitization of hypoxic cells in human tumours.
THE FIRST chemical sensitizing agent of
hypoxic tumour cells to reach full clinical
trial misonidazole (MISO)-has proved
to be neurotoxic, and the total dose which
may be given to patients must be limited
(Dische et al., 1977). A considerable effort
is currently being made to develop new
drugs which will show greater activity
and/or reduced toxicity and so allow
higher levels of sensitization to be reached
in hypoxic cells in human tumours.
Desmethylmisonidazole (the Roche ex-
perimental drug, Ro-05-9963, DESMISO)
is the first metabolite of MISO, and in
equimolar concentration is a radiosensi-
tizer of equal efficiency to MISO (Fowler
et al., 1976). The drug, however, combines
a lower lipophilicity (the octanol/water
partition coefficients are MISO 0 43,
DESMISO 0*1I) with a shorter half-life in
dogs and mice (Brown & Workman, 1980;
White & Workman, 1980). These qualities
should be associated with reduced neuro-
toxicity. Although there is some variation
in the findings concerning the incidence of
neurotoxicity in animal studies with this
drug, the most recent ones suggest that
DESMISO is significantly less toxic than
MISO (Dische et al., 1980).
We have recently shown that the drug
is well absorbed when given orally (Dische
et al., 1980). The peak concentration, at
about 1 h, was 80% of that seen with
MISO. The mean half-life of the drug in
plasma was found in the 3 subjects to be
6-0 h, compared with 10.4 for MISO.
These findings suggested that DESMISO
might prove to be a more efficient drug for
oral use as a hypoxic-cell sensitizer in man
than MISO. A clinical study to determine
drug levels in human tumours and in
cerebrospinal fluid (CSF) is now reported.
MATERIALS AND METHODS
Tumour biopsies were performed in 13
patients who presented advanced untreated
primary tumours or recurrent tumours. TheyDESMETHYLMISONlDAZOLE IN HUMAN TUMOURS
consisted of 6 carcinomas of breast, 5 carcin-
omas of the uterine cervix, 1 recurrent
rectal carcinoma and 1 malignant melanoma
on the lower leg. All patients gave their in-
formed consent, and all administrations were
coordinated with the radiotherapy which they
were receiving so that any benefit due to
radiosensitization of hypoxic cells would be
gained by the patient. In the 5 cervix cases
multiple biopsies were taken under general
anaesthesia; with the remaining cases local
anaesthesia was used in a few instances, but
in most no anaesthetic was required.
The samples were freed from contaminating
blood by absorption on blotting paper and
examined for homogeneity of appearance. A
representative portion was removed for histo-
logical examination. The specimens reaching
the laboratory for estimation of nitroimid-
azole concentration ranged from 20-1000 mg
but was usually 50-200 mg. In 6 cases biopsy
samples were taken at hourly intervals for
3 or 4 h. In 11 ofthe cases more than 1 speci-
men was obtained at the same time in order
to compare concentrations in different
tumour samples. A total of 60 samples were
taken from the 13 tumours.
The dose of DESMISO was 0-5-2-0 g and
the individual dose was usually calculated on
a basis of0 5 or 1 g/m2 ofsurface area. It was
given in an aqueous solution and blood
samples were taken for determination of
plasma concentration at half-hourly intervals
to 4 h and then at 6, 8 and 24 h after ad-
ministrations. Urine samples were collected
during a 24h period in some cases. The find-
ings in plasma and urine will be reported
separately.
One purpose of the work was to compare
concentrations in human tumours of DES-
MISO with those achieved with MISO. In
view ofthe variability which may be found in
the drug concentrations in tumour we did in
7 cases administer both drugs on the same
day. In 3 they were given simultaneously and
the tumours biopsied at hourly intervals, and
in 4 they were separated by 2-3 h and samp-
ling carried out at the currently regarded
optimum time for treatment after administra-
tion ofMISO, and the probable optimum time
for administration of DESMISO. Although
DESMISO was given in these cases in the
usual aqueous solution, the MISO was given
in capsules. This was because of the require-
ments of the drug-regulating authority, and
because it was intended that a practical
comparison of the potential use of DESMISO
against the current use of MISO should be
performed.
In 8 patients with a variety of malignant
disorders a lumbar puncture was required as
part of their medical management. The in-
formed consent of the patient was obtained
for the administration of a small dose of
DESMISO at a given interval before the
lumbar puncture. In some a number of blood
samples were taken in order to produce a
curve of plasma concentration with time, but
in most this was not possible. At the time of
lumbar puncture a blood sample was taken
and 0 5-1 ml of CSF for DESMISO estima-
tion.
All nitroimidazole concentrations in
tumour, blood and urine were determined by
high-performance liquid chromatography
(HPLC) using methods previously described
(Dische et al., 1979). Using this technique
both MISO and DESMISO concentrations
were determined in each sample of tumour or
blood in a single operation.
In 2 of the patients given MISO and
DESMISO before anaesthesia the interval
between administration of DESMISO and
anaesthesia was reduced to 1 h. This was per-
mitted by the anaesthetist, as the small
amount ofDESMISO given could be dissolved
in less than 4 ml. It was, however, found that
the administration coincided with the giving
of the premedication. The curve of DES-
MISO concentration in the plasma showed a
marked delay, no doubt related to gastric
delay due to the premedication, and the
tumour biopsies in these cases were of little
value.
RESULTS
Tumour concentration
With both MISO and DESMISO all
values were normalized to an administra-
tion of 1 g/m2. Fig. 1 shows a typical
result in a patient with a large ulcerated
carcinoma of the breast in which all the
material taken showed apparently fully
viable carcinoma by histological study.
The concentration of MISO in this case
rose steadily up to 4 h after administra-
tion, closely parallelling the plasma con-
centration. The concentration of DES-
MISO also follows the blood levels and
reaches a maximum at 2 h. In Fig. 2 we
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FIG. 1.-Case J 11. Advance(l ulcerated carcinoma of the breast. All levels inormalized to a dose of
1 g/m2. Both drugs given simultaneously. Left: MISO in plasma (A) andl in tumour (A). Right:
DESMISO in plasma (,>) and in tumouir (*).
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FIG. 2. Left: the concentration of DESMISO in 6 human tumours related to time after a(iministia-
tion. In 3 (0) all specimens appeared fully viable whilst in 3 (*) some necrosis wxas seen. Right:
the concentration of MISO in 3 human tumours related to time after administration. In one (A)
all specimens appeared fully viable wlilst in 2 (A) some necrosis was seen.
can compare the curve of tumour concen-
trations in 6 tumours with DESMISO and
in 3 of the same tumours with MISO. In
general the features already described may
be seen. We have examined the data for
any alteration with time in the ratio of
DESMISO concentration in tumour to
that in plasma, and none was seen; with
MISO we noted a slight but not significant
trend for improved tumour/plasma ratios
with time.
In work with MISO we have shown that
the tumour concentration is inversely
related to the amount of necrosis to be
observed histologically in the specimen
(Rich et al., 1981). All 60 samples in this
study were examined histologically, and
in each an estimate was made of the per-
centage of the material occupied by
obviously necrotic material. Fig. 3 shows
the tumour/plasma ratios for DESMISO
and MISO related to the amount of
necrosis. Where no necrosis was seen the
mean of 27 determinations of DESMISO
was 0.83, while with MISO the mean of
15 determinations was 0-82. With these
uI
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FIa. 3. Tumour: plasma concentration ratio
of DESMISO in 45 specimens (0) and of
MISO in 28 specimens (*) related to the
presence of necrosis seen histologically. In
27 DESMISO and 15 MISO results the
specimens showed no necrosis, and the
mean concentrations are shown to be
similar. There is a trend for high concen-
trations to be found with DESMISO when
specimens are 95-100% necrotic.
tumours the concentration of nitroimid-
azole seems little influenced until the
tissue was considered to be 95-100%
necrotic, when some low values were
obtained with both drugs but particularly
with MISO. Further information can be
gained as to the penetration of the drug
into necrotic tissue by examining the
records of those patients where multiple
biopsies were performed at once. The
largest number of biopsies at the same
time were performed in the cervix
cases, where it could easily be completed
under the general anaesthetic used for
routine examination of the patient. Un-
fortunately in 2 of the cases there was
delayed absorption of DESMISO because
the administration coincided with the
giving of the premedication. In the re-
maining 3 there was evidence of a better
penetration of DESMISO into necrotic
tissue. The observations in case J1O are
shown in Fig. 4.
The concentration of DESMISO in
CSF was determined on 1 occasion in 8
cases. In each the ratio of CSF to plasma
concentration was calculated. The results
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FIG. 4. Case J 10. Carcinoma of uterine
cervix. 0 5 g MISO given 4 h before and
0.5 g DESMISO given 2 h before biopsies
ofcervix performed.
are plotted in Fig. 5 in relation to a com-
posite curve of plasma concentration
derived from 16 studies with DESMISO.
We can compare this with a curve of
MISO plasma levels obtained in 10 ofthese
subjects, and a curve of CSF values calcu-
lated from the data of Ash et al. (1979).
When we compare the AUCs of plasma
concentration versus time ofthe two drugs
considered up to 48 h after administration,
we find a ratio of MISO to DESMISO of
1: 0.55. The ratio of AUC of CSF concen-
tration versus time of MISO to DESMISO
is 1:0-33.
DISCUSSION
In addition to the ready absorption
after oral administration already re-
ported, there seems to be a ready uptake
ofDESMISO in tumourtissue. The tumour
concentrations appear to rise and fall in
nearly all cases with the plasma concen-
tration. With the more rapid changes in
plasma concentration seen with DES-
MISO than with MISO, timing is more
critical. In management of the patients
here reported, radiotherapy has been given
60-90 min after administration. We are
considering a later administration (90 + 15
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F}o. 5.--A comparisoii of the levels in plasina ain(l ccrebros)pIlal fluid( follow-inig oral administration
of D)ESAIS() (left) ain(d M1IS() (riglit). All levels normalized to a (lose of 1 g/m2. W'itlh DESMISSO
mean plasma concentrations after a(lministration to 16 simbjects are sho-wn (c). Concentrations
in CSF fouin(d in 8 stubjects were calculatedl as a percentage of p)lasma concentration at time of
withdrawal ani(l are shlown here (+) as thtat percenitage of tie composite plasma curve. W'itlh MIS()
tile mean plasma concentrations after a(lministration to 10 sllbjects are sho1w n ( ). Tile CSF concen-
tration (lata of Asht et, al. (1979), which ineludle(d 19 1180() levels in tihe (SF of 5 patients, are
pmres,entedl in time sarne -way as fori DESMI() (-).
min) based oin our currenit work. The trend
towards higher concentrations in necrotic
tissue than with MISO encourages us to
believe that the drug will penetrate to
hypoxic cells in human tumours. We can-
not, however, be certain that penetration
of necrotic tissue and the passage to
hypoxic cells are similar processes.
Brown & Yu (1980) have recently sug-
gested that there is a lag between maxi-
mum concentration of nitroimidazoles in
animal tumours and the time for full
radiosensitization of hypoxic cells. Such
delay has been thought related to delay
in the passage of the drug into hypoxic
cells. Such observations cainnot be re-
peated with human tumours, but should
further laboratory work confirm the find-
ing, this delay will have to be considered
in the timing of radiotherapy after ad-
ministration of DESMISO.
In the experiments in which MISO and
DESMISO were both given to patients
and their concentrations in plasma and
tumour observed, DESMISO levels were
raised by demethylation of MISO to
DESMISO. After administration of MISO
an accumulation of DESMISO in plasma
and ttumotur occurs. The p)roportion in-
creases with time and wvill contribute to
radiosensitization. We have calculated
this contribution to amount to about 50
in the first 4 h after administration of
MISO, and do not believe that there is a
significant influence upon the results. The
techniqute ofadministration of 2 sensitizing
drugs on the same occasion in order to
make accurate comparison would seem to
us valuable in the general development of
chemical sensitizing agents. MISO must
remain as the standard against which new
agents cani be measured for radiosensitiza-
tion, pharmacokinetics and toxic effects.
In the laboratory MISO and DESMISO
have been shown to be of similar efficiency
as chemical hypoxic cell radiosensitizers
when tested in equimolar concentrations.
However, DESMISO is a smaller molecule,
so when equal amounts by wu.eight are
given DESMISO can be expected to be
70 more effective.
Tumour concentrations generally seem
to follow the plasma concentrations. If
plasma concentrations achieved with
DESMISO in the 1-2hperiod are compared
with those after an identical dose of
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MISO during the favoured period for
treatment at - 4 h, then DESMISO levels
are 85-90% ofthose with MISO. Consider-
ing the 7% increased effectiveness based
on the mol. wt, and a possibly greater
penetration of the drug into necrotic
tissue and perhaps into hypoxic cells, we
can for practical purposes consider that
administration of equal amounts of the 2
sensitizing drugs will lead to an approxi-
mately equal amount of hypoxic-cell
radiosensitization when radiotherapy is
given after the appropriate interval.
There is evidence in laboratory animals
and in man that the closest correlation
with toxicity lies with the AUC of plasma
concentration vs time. The reduction of
the AUC by 45% with DESMISO ought
to result in reduced toxicity. The AUC of
CSF concentration vs time is reduced by
67%, and this ought to allow further
reduction of cerebral neurotoxicity and
perhaps also peripheral neuropathy, if
uptake in peripheral nerves is also reduced.
These results give further support to the
view that DESMISO may prove to be a
more effective sensitizer in clinical practice
than MISO. Administration ofthe drug to
humans in amounts required to achieve
radiosensitization in a course of radio-
therapy is now indicated. The toxicological
study of this drug will be important not
only to help determine the potential ofthe
drug for clinical trial, but also to learn
whether the laboratory models for quanti-
tative estimate of toxic effects of chemical
sensitizers are relevant to man.
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